Skip to main content
. Author manuscript; available in PMC: 2012 Apr 1.
Published in final edited form as: J Viral Hepat. 2011 Apr;18(4):e52–e60. doi: 10.1111/j.1365-2893.2010.01358.x

Figure 1.

Figure 1

HCV RNA kinetics per viral response group per genotype. (A) and (C) early viral kinetics from initiation of therapy until day 15, in patients infected with HCV genotype-1 (GT-1) or genotype-3 (GT-3), respectively. (B) and (D) viral kinetics from initiation of therapy until week 12, in patients infected with HCV genotype-1 (GT-1) or genotype-3 (GT-3), respectively. * For difference between XXX and XXX (p<xxx). ** For difference between XXX and XXX (p<xxx). Vertical lines represent standard error of the mean. Already at day 15, patients who achieved SVR and were infected with HCV genotype 1 had significantly lower viral load than patients who were relapsers (REL) or nonresponders (NR) (p=0.012 and p=0.008, respectively). Among Gen 3 patients, viral load in SVR patients was significantly (p=0.014) lower than REL patients at day 29.